ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil.
Anatolia IVF, Ankara, Turkey.
Front Endocrinol (Lausanne). 2021 Mar 12;12:630550. doi: 10.3389/fendo.2021.630550. eCollection 2021.
To estimate the prevalence of low-prognosis patients according to the POSEIDON criteria using real-world data.
Multicenter population-based cohort study.
Fertility clinics in Brazil, Turkey, and Vietnam.
Infertile women undergoing assisted reproductive technology using standard ovarian stimulation with exogenous gonadotropins.
None.
Per-period prevalence rates of POSEIDON patients (overall, stratified by POSEIDON groups and by study center) and the effect of covariates on the probability that a patient be classified as "POSEIDON".
A total of 13,146 patients were included. POSEIDON patients represented 43.0% (95% confidence interval [CI] 42.0-43.7) of the studied population, and the prevalence rates varied across study centers (range: 38.6-55.7%). The overall prevalence rates by POSEIDON groups were 44.2% (group 1; 95% CI 42.6-45.9), 36.1% (group 2; 95% CI 34.6-37.7), 5.2% (group 3; 95% CI 4.5-6.0), and 14.4% (group 4; 95% CI: 13.3-15.6). In general, POSEIDON patients were older, had a higher body mass index (BMI), lower ovarian reserve markers, and a higher frequency of female factor as the primary treatment indication than non-POSEIDON patients. The former required larger doses of gonadotropin for ovarian stimulation, despite achieving a 2.5 times lower number of retrieved oocytes than non-POSEIDON patients. Logistic regression analyses revealed that female age, BMI, ovarian reserve, and a female infertility factor were relevant predictors of the POSEIDON condition.
The estimated prevalence of POSEIDON patients in the general population undergoing ART is significant. These patients differ in clinical characteristics compared with non-POSEIDON patients. The POSEIDON condition is associated with female age, ovarian reserve, BMI, and female infertility. Efforts in terms of diagnosis, counseling, and treatment are needed to reduce the prevalence of low-prognosis patients.
使用真实世界数据根据 POSEIDON 标准估算低预后患者的患病率。
多中心基于人群的队列研究。
巴西、土耳其和越南的生育诊所。
接受标准卵巢刺激和外源性促性腺激素的辅助生殖技术的不孕女性。
无。
每个周期 POSEIDON 患者的患病率（总体，按 POSEIDON 组和研究中心分层）以及协变量对患者被归类为“POSEIDON”的概率的影响。
共纳入 13146 名患者。POSEIDON 患者占研究人群的 43.0%（95%置信区间[CI]42.0-43.7），且患病率在各研究中心之间存在差异（范围：38.6-55.7%）。按 POSEIDON 组划分的总体患病率为 44.2%（组 1；95%CI42.6-45.9）、36.1%（组 2；95%CI34.6-37.7）、5.2%（组 3；95%CI4.5-6.0）和 14.4%（组 4；95%CI：13.3-15.6）。一般来说，POSEIDON 患者年龄较大，体重指数（BMI）较高，卵巢储备标志物较低，且女性因素作为主要治疗指征的频率高于非 POSEIDON 患者。尽管 POSEIDON 患者的获卵数比非 POSEIDON 患者低 2.5 倍，但他们需要更大剂量的促性腺激素进行卵巢刺激。逻辑回归分析显示，女性年龄、BMI、卵巢储备和女性不孕因素是 POSEIDON 状况的相关预测因素。
在接受 ART 的一般人群中，估计 POSEIDON 患者的患病率较高。与非 POSEIDON 患者相比，这些患者在临床特征上存在差异。POSEIDON 状况与女性年龄、卵巢储备、BMI 和女性不孕有关。需要在诊断、咨询和治疗方面做出努力，以降低低预后患者的患病率。
